HB Wealth Management LLC Acquires 70 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

HB Wealth Management LLC increased its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 6.1% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 1,209 shares of the biotechnology company’s stock after buying an additional 70 shares during the quarter. HB Wealth Management LLC’s holdings in Axon Enterprise were worth $378,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. LPL Financial LLC boosted its position in Axon Enterprise by 6.6% in the third quarter. LPL Financial LLC now owns 43,559 shares of the biotechnology company’s stock worth $8,668,000 after purchasing an additional 2,715 shares during the last quarter. Stifel Financial Corp raised its stake in Axon Enterprise by 2.4% during the 3rd quarter. Stifel Financial Corp now owns 21,961 shares of the biotechnology company’s stock valued at $4,370,000 after purchasing an additional 506 shares during the period. Advisors Asset Management Inc. raised its stake in Axon Enterprise by 18.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 18,650 shares of the biotechnology company’s stock valued at $3,711,000 after purchasing an additional 2,965 shares during the period. Ameriprise Financial Inc. raised its stake in Axon Enterprise by 10.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 379,286 shares of the biotechnology company’s stock valued at $75,474,000 after purchasing an additional 34,728 shares during the period. Finally, Kennedy Capital Management LLC raised its stake in Axon Enterprise by 4.4% during the 3rd quarter. Kennedy Capital Management LLC now owns 48,360 shares of the biotechnology company’s stock valued at $9,623,000 after purchasing an additional 2,047 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research note on Wednesday, April 24th. Argus assumed coverage on Axon Enterprise in a research note on Wednesday, March 13th. They issued a “buy” rating and a $380.00 price objective on the stock. StockNews.com downgraded Axon Enterprise from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. Morgan Stanley lifted their price objective on Axon Enterprise from $285.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, April 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $400.00 price objective on shares of Axon Enterprise in a research note on Tuesday, May 7th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $335.27.

Axon Enterprise Trading Up 0.2 %

Shares of AXON stock traded up $0.62 on Friday, hitting $297.18. 77,108 shares of the stock traded hands, compared to its average volume of 488,762. Axon Enterprise, Inc. has a twelve month low of $175.37 and a twelve month high of $329.87. The stock has a market capitalization of $22.43 billion, a PE ratio of 86.71 and a beta of 0.95. The firm’s 50-day moving average price is $294.68 and its two-hundred day moving average price is $285.92. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.95 by $0.20. The business had revenue of $460.74 million for the quarter, compared to analyst estimates of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The company’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.51 EPS. As a group, analysts anticipate that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

Insiders Place Their Bets

In other news, Director Julie A. Cullivan sold 993 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the sale, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Julie A. Cullivan sold 993 shares of Axon Enterprise stock in a transaction on Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the completion of the sale, the director now directly owns 4,553 shares of the company’s stock, valued at approximately $1,282,671.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeri Williams sold 308 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $310.07, for a total value of $95,501.56. Following the sale, the director now directly owns 1,607 shares in the company, valued at approximately $498,282.49. The disclosure for this sale can be found here. Insiders have sold 89,447 shares of company stock worth $27,684,677 over the last ninety days. Corporate insiders own 5.70% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.